25 results
Thumbnail

D1.02 - Prevalence of allergic respiratory disorders in urban V/s rural Indian population

Thumbnail

D1.03 - Sustainable and gluten free bread: Are legumes a hidden risk for occupational IgE-mediated respiratory allergy?

Thumbnail

D1.04 - Diagnostic approach for respiratory symptoms linked to microbial contamination in metalworking fluids

Thumbnail

D1.05 - Bet v 6 as a Marker of Pollen Cross-Reactivity in Southern Europe: Insights from a Birch-Free Region

Thumbnail

D1.07 - Profile of sensitization to inhalant allergens in Valencia: Analysis of 1.898 skin prick tests over one year

Thumbnail

D1.09 - Dynamics of pollen allergy in Ukraine during the full-scale invasion shows demand for diagnostics increased with changed sensitization patterns seen

Thumbnail

D1.10 - Tree pollen allergy profile in Ukraine assessed by large-scale molecular component analysis

Thumbnail

D1.11 - Age and Gender Patterns in Fungal Allergen Sensitization: A Study from Central Ukraine

Thumbnail

D1.13 - EHealth tools suitability and technologic innovation use in an Environmental Exposure Chamber

Thumbnail

D1.14 - Molecular Allergy Profiling of Pollen Sensitization in Cluj-Napoca

Thumbnail

D1.15 - Relationship between sensitization to peanuts and tree nuts in children with allergic diseases in a population of the Russian Federation

Thumbnail

D1.12 - Optimal Conventional Diagnostic Approach for Wheat Allergy in Chinese Children

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years